Restricted accessResearch articleFirst published online 2026
Establishment and characterization of a metabolic dysfunction-associated steatotic liver disease model in the male Korean field mouse ( Apodemus peninsulae ): A comparison with the male C57BL/6J mouse
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly serious global health issue. The establishment of accurate animal models is crucial for elucidating its pathogenesis and developing effective therapeutic strategies. Although mouse models are widely used in MASLD research, they exhibit significant differences from humans in metabolic traits and disease progression, limiting their ability to fully recapitulate key pathological features of MASLD. In this study, we established an MASLD model in Apodemus peninsulae using a high-fat diet (HFD) and compared it with the commonly used C57BL/6J mouse model. The results showed that A. peninsulae developed marked lipid metabolism disorders and liver function impairment as early as week 4 with an HFD intervention. Histological analysis revealed progressive steatosis, inflammatory infiltration, and early fibrosis from weeks 8 to 16, which was confirmed by oil red O, Masson’s trichrome, and Sirius red staining. In contrast, pathological progression in C57Bl/6J mice was slower, with milder fibrosis. Immunolabeling and inflammatory cytokine expression further indicated a more intense inflammatory response in A. peninsulae. Overall, A. peninsulae offers advantages, such as rapid disease induction and stable phenotypes, making it a promising animal model for studying early-stage MASLD. Its shorter modeling period and more pronounced steatosis and liver injury suggest it more closely mimics the early pathological changes seen in human MASLD.
Al ZarzourRHAhmadMAsmawiMZ, et al. Phyllanthus Niruri standardized extract alleviates the progression of non-alcoholic fatty liver disease and decreases atherosclerotic risk in Sprague-Dawley rats. Nutrients. 2017;9:766.
2.
AsgharpourACazanaveSCPacanaT, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016;65:579–588.
3.
CaddeoARomeoS.Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease. Clin Mol Hepatol. 2025;31:S76–S93.
4.
DongJLiMPengR, et al. ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARα- CPT1A axis. J Transl Med. 2024;22:196.
5.
EshraghianANikeghbalianSKazemiK, et al. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB. 2020;22:521–528.
6.
EstesCRazaviHLoombaR, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–133.
7.
FuruhashiMHotamisligilGS.Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489–503.
HwangBKwonMGChoMJ, et al. Hepatic PTP4A1 ameliorates high-fat diet-induced hepatosteatosis and hyperglycemia by the activation of the CREBH/FGF21 axis. Theranostics. 2023;13:1076–1090.
10.
IcardPCoquerelAWuZ, et al. Understanding the central role of citrate in the metabolism of cancer cells and tumors: an update. Int J Mol Sci. 2021;22:6587.
11.
ImYRHunterHde Gracia HahnD, et al. A systematic review of animal models of NAFLD Finds high-fat, high-fructose diets most closely resemble human NAFLD. Hepatology. 2021;74:1884–1901.
12.
KristiansenMNVeidalSSRigboltKT, et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol. 2016;8:673–684.
13.
LarterCZYehMM.Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol. 2008;23:1635–1648.
14.
LauJKZhangXYuJ.Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241:36–44.
15.
LazarusJVEkstedtMMarchesiniG, et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J Hepatol. 2020;72:14–24.
16.
LeeLAllooshMSaxenaR, et al. Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology. 2009;50:56–67.
17.
LiDHaoJYaoX, et al. Observations of the foraging behavior and activity patterns of the Korean wood mouse, Apodemus peninsulae, in China, using infra-red cameras. Zookeys. 2020;992:139–155.
18.
LiDJinZYangC, et al. Scatter-hoarding the seeds of sympatric forest trees by Apodemus peninsulae in a temperate forest in northeast China. Pol J Ecol. 2018;66:382–394.
19.
LiJZouBYeoYH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389–398.
20.
LiWGuanZBrissetJC, et al. A nonalcoholic fatty liver disease cirrhosis model in gerbil: the dynamic relationship between hepatic lipid metabolism and cirrhosis. Int J Clin Exp Pathol. 2018;11:146–157.
21.
LuJQZhangZB.Food hoarding behaviour of large field mouseApodemus peninsulae. Acta Theriologica. 2005;50:51–58.
22.
MatsuzakaTShimanoHYahagiN, et al. Cloning and characterization of a mammalian fatty acyl-CoA elongase as a lipogenic enzyme regulated by SREBPs. J Lipid Res. 2002;43:911–920.
23.
MengXHuangGWangZ, et al. Asymmetric competition for seeds between two sympatric food hoarding rodents: implications for coexistence. Integr Zool. 2023;18:817–830.
24.
MiaoLTargherGByrneCD, et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35:697–707.
25.
MoonYAShahNAMohapatraS, et al. Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins. J Biol Chem. 2001;276:45358–45366.
26.
ParkSJRhimS-JLeeE-J, et al. Home range, activity patterns, arboreality, and day refuges of the Korean wood mouse Apodemus peninsulae (Thomas, 1907) in a temperate forest in Korea. Mammal Study. 2014;39:209–217.
27.
PompiliSVetuschiAGaudioE, et al. Long-term abuse of a high-carbohydrate diet is as harmful as a high-fat diet for development and progression of liver injury in a mouse model of NAFLD/NASH. Nutrition. 2020;75–76:110782.
28.
RadhakrishnanSYeungSFKeJY, et al. Considerations when choosing high-fat, high-fructose, and high-cholesterol diets to induce experimental nonalcoholic fatty liver disease in laboratory animal models. Curr Dev Nutr. 2021;5:nzab138.
29.
RatziuVMarchesiniG.When the journey from obesity to cirrhosis takes an early start. J Hepatol. 2016;65:249–251.
30.
RinellaMELazarusJVRatziuV, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542–1556.
31.
RöhrigFSchulzeA.The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732–749.
32.
SanthekadurPKKumarDPSanyalAJ.Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 2018;68:230–237.
33.
SegnaniCIppolitoCAntonioliL, et al. Histochemical detection of collagen fibers by sirius red/fast green is more sensitive than Van Gieson or Sirius red alone in normal and inflamed rat colon. PLoS ONE. 2015;10:e0144630.
34.
SofticSStanhopeKLBoucherJ, et al. Fructose and hepatic insulin resistance. Crit Rev Clin Lab Sci. 2020;57:308–322.
35.
TakahashiYSoejimaYFukusatoT.Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2012;18:2300–2308.
36.
TargherGByrneCDTilgH.MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691–702.
37.
TavaresTBSantosIBde BemGF, et al. Therapeutic effects of acai seed extract on hepatic steatosis in high-fat diet-induced obesity in male mice: a comparative effect with rosuvastatin. J Pharm Pharmacol. 2020;72:1921–1932.
38.
TilgHPettaSStefanN, et al. Metabolic dysfunction-associated steatotic liver disease in adults: a review. JAMA. 2026;335:163–174.
39.
Van De VlekkertDMachadoEd’AzzoA.Analysis of generalized fibrosis in mouse tissue sections with Masson’s trichrome staining. Bio Protoc. 2020;10:e3629.
YoshidaYMatsunagaNNakaoT, et al. Alteration of circadian machinery in monocytes underlies chronic kidney disease-associated cardiac inflammation and fibrosis. Nat Commun. 2021;12:2783.
42.
YounossiZMGolabiPde AvilaL, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793–801.
43.
YounossiZMKoenigABAbdelatifD, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
44.
ZhangLWuXLiaoS, et al. Tree shrew (Tupaia belangeri chinensis), a novel non-obese animal model of non-alcoholic fatty liver disease. Biol Open. 2016;5:1545–1552.
45.
ZhongFZhouXXuJ, et al. Rodent models of nonalcoholic fatty liver disease. Digestion. 2020;101:522–535.
